4 assets in Gastric Squamous Cell Carcinoma

Therapeutic assets addressing Gastric Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Gastric Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Gastric Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Plx-61639 Gastric Squamous Cell Carcinoma	Plexium, Inc.	P1	CC (43)
prt7732 Gastric Squamous Cell Carcinoma	Prelude Therapeutics	P1	CC (43)